NEW

Switch to Dark

Pricing

Learn

BMY - Bristol-Myers Squibb Co

301

$59.37

-$0.34 (-0.569%)

At market close

$59.19

-$0.18 (-0.306%)

After Hours 3/18/26, 10:59 PM

3.86/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BMY

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Key Data & Metrics

Market Cap

$120.91B

Industry

Pharmaceuticals

EPS (TTM)

$3.46

P/E (TTM)

17.14

Div & Yield

$2.52 (4.24%)

FCF Payout Ratio

39.95%

P/S (TTM)

2.51

P/B

6.54

Diluted Shares

2.04B

Ex-Dividend

2026-04-02

Next Earnings

04-30

Forward P/E

9.74

Payout Ratio

72.75%

P/FCF (TTM)

9.41

FCF Yield

10.62%

Earnings Yield

5.83%

52 Week Range

Score Card

Explore Scores Tab

3.86

Good

Bristol-Myers Squibb Co has seen its revenue decline by -0.22% over the past year, which means the company is losing sales/customers. However, it has seen its operating income increase by 49.54% over the past year, which suggests its operations are becoming much more profitable.

Valuation Model

Key Score

3.00

Average

Management

4.00

Good

Growth

4.00

Good

Profitability

3.00

Average

Fin. Health

1.00

Very Bad

Dividends

3.00

Average

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

14 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:24:46

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:23:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:23:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:22:05

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:21:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:20:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:19:19

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:18:38

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:17:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:17:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:16:14

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-12 16:15:16

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$78.75

32.6%

Avg:

$62.03

4.5%

Low:

$33.43

-43.7%

(% change is relative to the current stock price: $59.37)

Analyst Recommendations

Go to Analyst Tab

3.53

Good

17%

Strong Buy (6)

25%

Buy (9)

53%

Hold (19)

6%

Sell (2)

0%

Strong Sell (0)

About

Website
https://www.bms.com
Address
Route 206 And Province Line Road, Princeton NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=14272

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

IPO Date

1980-03-17

Industry

Pharmaceuticals

Total Employees

32,500

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences